TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE B-

NCT07161544: A Study of AAVB-039 in Participants With Stargardt Disease (STGD1)

Sponsor: AAVantgarde Bio Srl · Phase: PHASE1/PHASE2 · Area: CARDIOLOGY_METABOLIC · Target Enrollment: 75 pts

Competing Trials Overlap

8 Active Trials

Excess Burn Exposure

$1,241,680

Rescue Site Savings

+$818,380

Unlock Full NCT07161544 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07161544 Rescue Dossier →